Off the Pitch: Why Cheering for the World Cup Is Good for Mind and Body
World Cup fever is heating up once again. Whether gathering on the streets, at home, in the workplace, or at local cafes, millions are sharing the...
Search results for "investment strategy"
Eli Lilly to Acquire GC Biopharma’s Curevo Vaccine in Blockbuster $1.5 Billion Deal
GC Biopharma’s U. S. affiliate, Curevo Vaccine, is set to be acquired by global pharmaceutical giant Eli Lilly in a deal valued at up to $1.
Oscotec Ramps Up R&D: What Lies Beyond the Success of Lazertinib?
“It doesn’t end with lazertinib. Keep an eye out for the next candidate in line.” Oscotec is aggressively channeling...
Rejuran Cosmetics Sales Surge 51%: PharmaResearch Finds New Growth Engine
PharmaResearch is successfully diversifying its business model, transitioning from a medical device-centric structure...
K-Pharma Sets Sights on Veterinary Market: Daewoong Pharmaceutical Leads the Charge
More than 10 South Korean pharmaceutical companies are pivoting toward veterinary medicine as a strategic growth engine.
Celltrion to Double Production Capacity with 1.2 Trillion Won Investment
Celltrion has announced a massive expansion across three of its major facilities in South Korea and the United States,...
Alteogen Poised for Surge in Milestone Revenue as Keytruda Qlex and Biosimilars Gain Momentum
Alteogen is set to accelerate its financial growth this year, driven by a surge in milestone payments and royalty...
Launch of 'TrumpRX' Sells Drugs at Steep Discounts: Will Celltrion and Samsung Biologics Face Price Pressure?
The prescription drug sales platform 'TrumpRX', named after U. S. President Donald Trump, has officially launched.
Capture the 0.02% Micro Signal in Blood...Bio Venture GraBis Challenging Early Cancer Diagnosis
“If you miss one tiny signal, you could lose a life (Missing one tiny signal Cost a Life).
Next-Generation Precision Medicine for Cancer Treatment... Amgen Acquires UK Biotech for 1 Trillion Won
Global pharmaceutical company Amgen is acquiring a UK biotech for up to $840 million (approximately 1.